Table 2.
Short-term outcomes within 30 days postoperation.
| Clinical outcomes | Urokinase-type plasminogen activator (45) | Tissue-type plasminogen activator (41) | p-Value |
|---|---|---|---|
| Residue HV on day 1 (mL) | 31.3 ± 8.9 | 33.8 ± 9.1 | 0.396 |
| ER on day 1 (%) | 41.9 ± 10.3 | 40.7 ± 8.8 | 0.711 |
| Residue HV after application of agents (mL) | 9.7 ± 4.9 | 11.6 ± 6.5 | 0.296 |
| ER after application of agents (%) | 82.6 ± 7.9 | 79.9 ± 9.5 | 0.332 |
| PHE on day 7 (mL) | 66.1 ± 22.4 | 68.9 ± 19.1 | 0.687 |
| Times of usage (times) | 5.4 ± 2.2 | 5.6 ± 2.1 | 0.829 |
| Catheter-retained time (h) | 40.4 ± 12.4 | 42.9 ± 13.9 | 0.552 |
| Recurrence of ICH, n (%) | 2 (4.4) | 2 (4.9) | 0.924 |
| Gastrointestinal bleeding, n (%) | 5 (11.1) | 4 (9.8) | 0.838 |
| Renal failure, n (%) | 1 (2.2) | 1 (2.4) | 0.947 |
| Intracranial infection, n (%) | 2 (4.4) | 1 (2.4) | 0.613 |
| Pulmonary infection, n (%) | 4 (8.7) | 3 (7.3) | 0.790 |
| Epilepsy, n (%) | 7 (15.6) | 5 (12.2) | 0.653 |
| Hospitalization length (day) | 9.2 ± 2.9 | 9.4 ± 2.3 | 0.862 |
| Total expenditure (¥, thousand Yuan) | 42.6 ± 5.4 | 47.0 ± 6.2 | 0.029 |
HV, hematoma volume; ER, evacuation rate; PHE, perihematomal edema; ICH, intracerebral hemorrhage.